Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2022-10-11 Interim / Quarterly Rep…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
EUROBIO SCIENTIFIC: H1 2022 RESULTS CONTINUED GROWTH OF NON-COVID ACTIVITY
Interim / Quarterly Report Classification · 95% confidence The document is a press release titled 'H1 2022 RESULTS' issued by Eurobio Scientific. It provides a comprehensive summary of the company's financial performance for the first half of the year, including detailed tables for revenue, EBITDA, net income, and cash position. It also includes management commentary on business trends, acquisitions, and future outlook. Since it contains substantive financial data and analysis for an interim period (H1 2022), it is classified as an Interim/Quarterly Report. H1 2022
2022-10-11 English
EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DE GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA
M&A Activity Classification · 99% confidence The document is a press release dated October 3, 2022, announcing the finalization of the acquisition of GenDx by Eurobio Scientific. It details the strategic rationale, financial terms (€135 million acquisition price, €90 million bank loan), business synergies, and includes quotes from management and advisors. This type of announcement, detailing a significant corporate transaction (M&A), fits best under the 'M&A Activity' category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific corporate action announcement.
2022-10-03 French
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
M&A Activity Classification · 99% confidence The document is a press release dated October 3, 2022, announcing the finalization of the acquisition of GenDx by Eurobio Scientific. It details the transaction terms, financing (€90 million bank loan), strategic rationale (complementarity, growth potential), and includes forward-looking statements and contact information. This type of announcement, detailing a significant corporate transaction (M&A), is typically classified under Merger & Acquisition Activity (TAR). It is not a standard periodic report (10-K, IR, ER) nor a general regulatory filing (RNS), but a specific corporate action announcement.
2022-10-03 English
EUROBIO SCIENTIFIC SIGNE UN ACCORD EN VUE D’ACQUERIR GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA
M&A Activity Classification · 99% confidence The document is a press release dated August 17, 2022, announcing that Eurobio Scientific has signed an agreement to acquire 100% of GenDx for 135 million euros. It details the strategic rationale, financing structure (cash and bank loan), and provides quotes from management and advisors. This type of announcement, detailing a significant corporate transaction (acquisition/merger), falls under the M&A Activity category. The code for M&A Activity is TAR.
2022-08-17 French
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
M&A Activity Classification · 99% confidence The document is a press release dated August 17, 2022, announcing that Eurobio Scientific has signed an agreement to acquire 100% of GenDx for 135 million euros. It details the strategic rationale, financial terms (cash and bank loan), expected synergies, and includes quotes from management and advisors. This type of announcement, detailing a significant corporate transaction (Merger or Acquisition), aligns perfectly with the 'M&A Activity' definition. It is not an Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR) as it focuses on a transaction, not periodic financial results. It is too detailed and specific to be a general Regulatory Filing (RNS) or a Report Publication Announcement (RPA). Therefore, the most appropriate classification is TAR (M&A Activity).
2022-08-17 English
Eurobio Scientific: FIRST HALF TURNOVER OF € 83.6 MILLION MAINTAINED AT A HIGH LEVEL
Earnings Release Classification · 98% confidence The document is a press release dated July 25, 2022, presenting the 'consolidated half-year turnover as at June 30, 2022.' It contains key financial highlights, comparative figures for H1 2021 vs H1 2022, operational commentary, and a forward-looking statement/disclaimer. This structure is characteristic of an initial announcement of periodic financial results, focusing on key figures rather than the comprehensive detail found in a full quarterly report (IR). Therefore, it aligns best with the Earnings Release (ER) category. H2 2022
2022-07-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.